No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.

[1]  C. Stadelmann,et al.  Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis , 2010, Neurology.

[2]  G. Giovannoni,et al.  Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. , 2009, Brain : a journal of neurology.

[3]  D. Hafler,et al.  Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. , 2009, Brain : a journal of neurology.

[4]  P. Sundström,et al.  Antibodies to specific EBNA-1 domains and HLA DRB1⁎1501 interact as risk factors for multiple sclerosis , 2009, Journal of Neuroimmunology.

[5]  K. Schmierer,et al.  Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI , 2009, Neurology.

[6]  J. Lünemann,et al.  EBV in MS: guilty by association? , 2009, Trends in immunology.

[7]  S. Cepok,et al.  Varicella zoster virus is not a disease‐relevant antigen in multiple sclerosis , 2009, Annals of neurology.

[8]  W. Valdar,et al.  Association of Infectious Mononucleosis with Multiple Sclerosis , 2009, Neuroepidemiology.

[9]  J. Lünemann,et al.  EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2 , 2008, The Journal of experimental medicine.

[10]  J. Sepulcre,et al.  Antibodies against Epstein–Barr virus and herpesvirus type 6 are associated with the early phases of Multiple Sclerosis , 2007, Journal of Neuroimmunology.

[11]  R. Reynolds,et al.  Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain , 2007, The Journal of experimental medicine.

[12]  P. Brennan,et al.  Epstein‐Barr virus infection and risk of lymphoma: Immunoblot analysis of antibody responses against EBV‐related proteins in a large series of lymphoma subjects and matched controls , 2007, International journal of cancer.

[13]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part I: The role of infection , 2007, Annals of neurology.

[14]  H. Zebroski,et al.  Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. , 2007, Blood.

[15]  S. Hauser,et al.  The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.

[16]  E. Kremmer,et al.  The antibody 2B4 directed against the Epstein–Barr virus (EBV)‐encoded nuclear antigen 1 (EBNA1) detects MAGE‐4: implications for studies on the EBV association of human cancers , 2006, The Journal of pathology.

[17]  J. Lünemann,et al.  Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. , 2006, Brain : a journal of neurology.

[18]  C. Poser.  Revisions to the 2001 McDonald diagnostic criteria. , 2006, Annals of neurology.

[19]  Jaap M Middeldorp,et al.  Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field Screening , 2006, Journal of Clinical Microbiology.

[20]  D. Spiegelman,et al.  Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. , 2005, JAMA.

[21]  K. Büssow,et al.  Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. , 2005, The Journal of clinical investigation.

[22]  J. Dillner,et al.  An altered immune response to Epstein-Barr virus in multiple sclerosis , 2004, Neurology.

[23]  E. Bloemena,et al.  Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses , 2001, Journal of Virology.

[24]  B. Plachter,et al.  Cross-Reactivity of Epstein-Barr Virus-Specific Immunoglobulin M Antibodies with Cytomegalovirus Antigens Containing Glycine Homopolymers , 2001, Clinical Diagnostic Laboratory Immunology.

[25]  K. Heilman,et al.  Epstein–Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis , 2000, Journal of the Neurological Sciences.

[26]  Jaap M Middeldorp,et al.  Molecular Fine-Specificity Analysis of Antibody Responses to Human Cytomegalovirus and Design of Novel Synthetic-Peptide-Based Serodiagnostic Assays , 1999, Journal of Clinical Microbiology.

[27]  Jaap M Middeldorp,et al.  Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. , 1994, The Journal of infectious diseases.

[28]  Jaap M Middeldorp,et al.  Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure , 1993, Journal of virology.

[29]  M. Akiyama,et al.  A Positive Correlation between the Precursor Frequency of Cytotoxic Lymphocytes to Autologous Epstein‐Barr Virus‐Transformed B Cells and Antibody Titer Level against Epstein‐Barr Virus‐Associated Nuclear Antigen in Healthy Seropositive Individuals , 1993, Microbiology and immunology.

[30]  Jaap M Middeldorp,et al.  Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein‐Barr virus capsid antigen complex , 1993, Journal of medical virology.

[31]  R. Meloen,et al.  Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides. , 1988, Journal of virological methods.

[32]  G. Rhodes,et al.  Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen. , 1986, The Journal of clinical investigation.

[33]  Jaap M Middeldorp,et al.  Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay , 1984, Journal of clinical microbiology.